Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subdermal Cefazolin for P. acnes in Shoulder Surgery
NCT03853096Phase 1Unknown
- Sponsor
- University of British Columbia
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Reversible Covalent Inhibitors
01
Overview
Phase 1, open-label, single-arm trial of cefazolin in surgical site infection (SSI) and Microbial Colonization (MC), sponsored by University of British Columbia. Primary endpoint: Change in Propionibacterium acnes colony count at 60 minutes. Status: unknown.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)Microbial Colonization (MC)
Beyond the preview
Go deeper on NCT03853096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853096.